Pregabalin Capsule
Product Images NDC 70518-4654

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4654). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm1 (Pregabalin 100mg 70518 4654 00)

Pregabalin 100 mg capsules packaging label showing quantity of 30 capsules. The label includes the NDC 70518-4654-00 and states the capsules are orange. It is labeled for prescription use only (RX only) and repackaged by RemedyRepack Inc., Indiana, PA. Storage instructions and caution about drug transfer are also present.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Pregabalin Capsule C-V, 100 mg, oral capsule form, packaged as 30 capsules. The label includes the NDC number 70518-4654-01. It is labeled for prescription use only and repackaged by RemedyRepack Inc. The label advises storage and child safety information and includes manufacturer details for Camber Pharma, Inc.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin dosages and placebo. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, illustrating differing effectiveness across dosages.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A Kaplan-Meier survival curve graph comparing Pregabalin and Placebo over 180 days. The y-axis shows the estimated percentage of subjects without LTR (loss to response), and the x-axis represents days. Two lines, one solid (Pregabalin) and one dashed (Placebo), depict differences in subject outcomes over time.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percent of subjects improved over time from baseline to Week 12 using the Brief Overall Change in Fibromyalgia (BOCF) scale. The x-axis represents the percent improved, and the y-axis shows the percent of subjects improved. Two lines compare Pregabalin (solid line) versus Placebo (dotted line).*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph displaying the percent of subjects improved on the vertical axis against the percent improved from baseline to week 16 on the horizontal axis. Two lines represent data for Pregabalin and placebo, indicating the treatment effect over time, with Pregabalin showing a higher improvement rate than placebo.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline for Pregabalin 100 mg taken three times a day versus placebo. The y-axis represents the percent of patients improved, and the x-axis denotes the percent improvement in pain from baseline, with distinct lines for each treatment group.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph showing the percentage of patients improved plotted against the percent improvement in pain from baseline. Four lines represent different treatments: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and placebo, illustrating varying levels of patient improvement by dose.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

Line chart depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing trends in patient improvement over increasing pain relief percentages.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line chart depicting the percent improvement in pain from baseline on the x-axis against the percent of patients improved on the y-axis. Three lines represent data for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing comparative effectiveness in patient pain improvement.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

Bar charts from two studies (Study E1 and Study E3) display responder rates (%) on the vertical axis for different dosages of Pregabalin compared to placebo. Study E1 shows rates for placebo and daily doses from 50 mg to 600 mg administered twice daily (BID). Study E3 compares placebo with 600 mg/day taken twice daily (BID) and three times daily (TID). The charts indicate increasing responder rates with higher Pregabalin doses.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A graph illustrating the median percentage change in seizure reduction from baseline versus dose (mg/day) in four studies labeled E1 BID, E2 TID, E3 BID, and E3 TID. The chart shows increasing seizure reduction percentages as the dose increases up to 600 mg/day, with significant p-values indicated for data points. The dose of 0 mg/day corresponds to placebo.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A vertical bar chart showing responder rates (%) for three groups: Placebo (22.6%, N=93), 2.5 mg/kg/day (29.1%, N=103), and 10 mg/kg/day (40.6%, N=96). The y-axis represents responder rate percentages, and the x-axis shows the treatment groups with sample sizes.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares four treatments: Pregabalin 600 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, showing the distribution of patient responses across levels of pain improvement.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of Pregabalin showing a five-carbon chain with an amino group (NH2), a methyl group (CH3) attached to the second carbon, and a carboxyl group (COOH) at the end of the chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.